GTS Securities’s Arcus Biosciences RCUS Stock Holding History

GTS Securities’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,170	Closed	-$218K	–	4339
2023 Q3	$218K	Buy	+12,170	New	+$245K	﹤0.01%	3343

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities's RCUS Position: Q4 2023 in Review

GTS Securities sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 12,170 shares — an estimated $218K sold.

GTS Securities first reported a position in RCUS in Q3 2023 and held it in 1 quarter. The position peaked at $218K in Q3 2023. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

GTS Securities reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 12,170 Arcus Biosciences shares in Q4 2023, an estimated $218K.
GTS Securities first reported a position in Arcus Biosciences in Q3 2023 and held it in 1 quarter.
GTS Securities's Arcus Biosciences position peaked at $218K in Q3 2023.
185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.